Clinical Trial Update: Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

Phase II study evaluating lenalidomide (Revlimid) combined with rituximab in relapsed or refractory chronic lymphocytic leukemia has completed enrollment, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Revlimid (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: University of California, San Diego | Conditions: Chronic Lymphocytic Leukemia, CLL | Phase 2 | Status: COMPLETED | Results posted: 2018-10-23